207_Combined course Presentations

PD-1 inhibitors and RT

 PD-L1 expression is a prognostic factor in resected NSCLC and a predictive factor for efficacy of therapies targeting PD-1 and PD-L1 in metastatic NSCLC.  The prognostic value of PD-L1 expression in patients with NSCLC treated with radiotherapy (RT) and chemotherapy (CT) has not been explored . immune microenvironment is involved in mechanisms underlying efficacy of RT and CT , suggesting that PD-L1 expression may modulate response to these treatments.  Tumor

Randomized data needed due to lack of historical baseline and recent stage migration